MCRB Seres Therapeutics Inc.

3.46
-0.02  -1%
Previous Close 3.48
Open 3.46
Price To Book -13.31
Market Cap 241,900,399
Shares 69,913,410
Volume 208,801
Short Ratio
Av. Daily Volume 359,606
Stock charts supplied by TradingView

NewsSee all news

  1. Flagship Pioneering Unveils Cygnal Therapeutics

    CAMBRIDGE, Mass., Oct. 8, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today unveiled Cygnal Therapeutics. Founded in 2017 in Flagship Labs, Flagship's innovation foundry,

  2. Flagship Pioneering Unveils Omega Therapeutics and Appoints Seasoned BioPharma Executive Mahesh Karande as President and Chief Executive Officer

    Omega Therapeutics is unleashing the human genome's native capacity to regulate genes and cure disease for a new era of genomic medicine The Company's platform is focused on precise tuning of Insulated Genomic

  3. 4BIO Capital raises $50 million in first close of new advanced therapies fund

    Press Release 4BIO Capital raises $50 million in first close of new advanced therapies fund             4BIO Ventures II fund solely focused on advanced therapies targeting $150 million final close 9 September 2019

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due early 2020.
SER-109 - ECOSPOR III
Recurrent C. Difficile infection
Phase 2b data due 3Q 2020.
SER-287
Mild-to-Moderate Ulcerative Colitis
Phase 1b data due 2H 2020.
SER-401
Melanoma

Latest News

  1. Flagship Pioneering Unveils Cygnal Therapeutics

    CAMBRIDGE, Mass., Oct. 8, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today unveiled Cygnal Therapeutics. Founded in 2017 in Flagship Labs, Flagship's innovation foundry,

  2. Flagship Pioneering Unveils Omega Therapeutics and Appoints Seasoned BioPharma Executive Mahesh Karande as President and Chief Executive Officer

    Omega Therapeutics is unleashing the human genome's native capacity to regulate genes and cure disease for a new era of genomic medicine The Company's platform is focused on precise tuning of Insulated Genomic

  3. 4BIO Capital raises $50 million in first close of new advanced therapies fund

    Press Release 4BIO Capital raises $50 million in first close of new advanced therapies fund             4BIO Ventures II fund solely focused on advanced therapies targeting $150 million final close 9 September 2019